Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Safety and Efficacy of FETO in CDH: A Phase III Trial

NCT: NCT06884423 · RECRUITING

NCT IDNCT06884423
StatusRECRUITING
Start Date2025-04-07
Completion2032-04
SponsorHolly L Hedrick, MD (OTHER)
First posted
Last updated

Brief Summary

Congenital diaphragmatic hernia (CDH) is a birth defect characterized by the development of a hole in the diaphragm, the breathing muscle that separates the chest from the abdomen. As a result, organs in the abdomen can move into the chest and press on the developing lungs. This prevents the lungs from growing and developing normally. In severe cases, CDH can lead to serious disease and death at birth. For these babies, treatment before birth may allow the lungs to grow enough before birth so these children are capable of surviving and thriving.

Frequently Asked Questions

What is Safety and Efficacy of FETO in CDH: A Phase III Trial?

Safety and Efficacy of FETO in CDH: A Phase III Trial is a clinical trial registered under NCT06884423. Current status: RECRUITING.

What is the status of NCT06884423?

The current status of NCT06884423 (Safety and Efficacy of FETO in CDH: A Phase III Trial) is: RECRUITING.

When did Safety and Efficacy of FETO in CDH: A Phase III Trial start?

Safety and Efficacy of FETO in CDH: A Phase III Trial started on 2025-04-07.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.